Olymvax
Major Drugs - N/A, N/A, CN
Olymvax Details
Founded in 2009, Olymvax Biopharmaceuticals Inc. is a National High-tech Enterprise, focusing on the R&D, Production and Marketing of human-use vaccines. The factory covers an area of 52666 square meters, with 40,000 square meters' GMP facility. Adhering to the business philosophy of "strengthening management, committing to improvement and pursuing the highest quality", Olymvax aims to be an "internationally well-known and domestically leading" vaccine supplier. The construction and management of the production infrastructure conforms to Chinese GMP 2010, and is designed following Euro-American advanced criteria, preparing for the global marketing of products. When it comes to R&D, Olymvax has set up an international strategy on business development and initiated various projects around this goal. Up to date, the company has cooperated with entities with strong scientific ability around the world to develop both first-in -class vaccines and vaccines most in need. Olymvax is keeping integrating global resources, maintaining cooperation with all parties, striving to achieve technological breakthroughs for the development of vaccines.By now Olymvax has sucessfully launched 2 products, Tetanus vaccine and Haemophilus influenzae b vaccine. Still numerous vaccines are in the pipeline, including recombinant Staphylococcus Aureus Vaccine,which is in a phase II clinical trail and Group A Streptococcus Vaccine, as well as Streptococcus pneumoniae vaccine, pertussis vaccine etc.
Olymvax Technologies
Load Balancers
Microsoft-IIS
Other
Mobile Friendly